Bristol-Myers Squibb (NYSE:BMY) trades down 0.6%

Shares of Bristol-Myers Squibb (NYSE:BMY – Get Free Report ) traded down 0.6% on Friday. The company traded as high as $40.75 and last traded at $41.22. 2,771,899 shares changed hands in mid-day trading, down 82% from the session’s average volume of 15,318,464 shares. Shares previously closed at $41.48.

Analysts set new price targets

A number of equities research analysts have weighed in on the stock. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Barclays reduced their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 23rd. Finally, BMO Capital Markets cut their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note from Friday, April 26. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $60.00, according to MarketBeat.com.

See the latest stock report on BMY

Bristol-Myers Squibb stock falls 0.7%

The company’s fifty day moving average price is $44.50 and its 200 day moving average price is $48.73. The stock has a market cap of $83.52 billion, a P/E ratio of -13.29, a price-to-earnings-growth ratio of 14.04 and a beta of 0.43. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99, and a current ratio of 1.11.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. In the same quarter last year, the business posted EPS of $2.05. The company’s revenue for the quarter was up 4.7% year over year. equities analysts predict that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Institutional investors are weighing in on Bristol-Myers Squibb

Large investors have recently modified their holdings in the business. Northwest Financial Advisors bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $27,000. ESL Trust Services LLC purchased a new stake in Bristol-Myers Squibb in the 1st quarter worth $27,000. Accordant Advisory Group Inc acquired a new stake in Bristol-Myers Squibb in the 1st quarter worth $31,000. Pacific Capital Wealth Advisors Inc. purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at $34,000. Finally, Turtle Creek Wealth Advisors LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter valued at $40,000. Institutional investors own 76.41% of the company’s shares.

About Bristol-Myers Squibb

(Get a free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Read more

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.